Aderans Research Institute was issued a patent on April 3,2007 for their bioabsorbable scaffolds. These scaffolds are used in hair cloning procedures to ensure that the cultured cells are kept in place in order for a new hair follicle to be formed.
According to the patent: The “bioabsorbable scaffolds are useful for the tissue engineering of new hair follicles and to methods for their manufacture and to methods of their use in creating new hair. More specifically it relates to new and useful bioabsorbable porous structures that have the correct architecture to facilitate culturing of the appropriate follicle progenitor cells and their development into normal, functional, hair-producing follicles. The invention also relates to methods of making and using bioabsorbable scaffolds to implant and grow new hair follicles in vitro and in vivo.”
“These tiny scaffolds are essentially the key to being able to grow new hair follicles because without them the cells cannot be held together after being injected into the scalp. New hair follicles get created in a specific process that results from the interaction between different cells. If these cells cannot be held together in the same place by some mechanism, then they will simply disperse from the point of injection and no new hair follicle will be formed.”
So if ARI already knew that there was a missing link to using just dermal cells and they aquire ICX-TRC (already in phase II trials) would that put ARI in a position to release some form of hybrid TRC protocol in a reasonable ammount of time (If it worked)? Or would ARI have to start clinical trials all over?